Thromboembolism is the leading cause of cardiovascular mortality.Currently,for the lack of targeting,short half-life,low bioavailability and high bleeding risk of the classical thrombolytic drugs,pharmacological throm...Thromboembolism is the leading cause of cardiovascular mortality.Currently,for the lack of targeting,short half-life,low bioavailability and high bleeding risk of the classical thrombolytic drugs,pharmacological thrombolysis is usually a slow process based on micro-pumping.In addition,frequently monitoring and regulating coagulation functions are also required during(and after)the process of thrombolysis.To address these issues,a targeted thrombolytic and anticoagulation nanoplatform(UCATS-UK)is developed based on upconversion nanoparticles(UCNPs)that can convert 808 or 980 nm near-infrared(NIR)light into UV/blue light.This nanoplatform can target and enrich in the thrombus site.Synergistic thrombolysis and anticoagulation therapy thus could be realized through the controlled release of urokinase(UK)and nitric oxide(NO).Both in vitro and in vivo experiments have confirmed the excellent thrombolytic and anticoagulative capabilities of this multifunctional nanoplatform.Combined with the unique fluorescent imaging capability of UCNPs,this work is expected to contribute to the development of clinical thrombolysis therapy towards an integrated system of imaging,diagnosis and treatment.展开更多
基金the National Natural Science Foundation of China(No.31860263 to Xiaolei Wang,No.82060095 to Weimin Zhou)Key Youth Project of Jiangxi Province(20202ACB216002 to Xiaolei Wang)+1 种基金Natural Science Foundation of Jiangxi Province(911135755018 to Weimin Zhou)Jiangxi Provincial Graduate Innovation Special Fund(YC2020-B053 to Shichen Liu).
文摘Thromboembolism is the leading cause of cardiovascular mortality.Currently,for the lack of targeting,short half-life,low bioavailability and high bleeding risk of the classical thrombolytic drugs,pharmacological thrombolysis is usually a slow process based on micro-pumping.In addition,frequently monitoring and regulating coagulation functions are also required during(and after)the process of thrombolysis.To address these issues,a targeted thrombolytic and anticoagulation nanoplatform(UCATS-UK)is developed based on upconversion nanoparticles(UCNPs)that can convert 808 or 980 nm near-infrared(NIR)light into UV/blue light.This nanoplatform can target and enrich in the thrombus site.Synergistic thrombolysis and anticoagulation therapy thus could be realized through the controlled release of urokinase(UK)and nitric oxide(NO).Both in vitro and in vivo experiments have confirmed the excellent thrombolytic and anticoagulative capabilities of this multifunctional nanoplatform.Combined with the unique fluorescent imaging capability of UCNPs,this work is expected to contribute to the development of clinical thrombolysis therapy towards an integrated system of imaging,diagnosis and treatment.
